20-F: SHL Telemedicine Appoints New CEO, Reports Financial Results, and Faces Challenges in 2024

SHL Telemedicine reports financial results for 2024, appoints a new CEO, and navigates challenges including a goodwill impairment in its German operations and a voluntary delisting from the Nasdaq.

Summary

• SHL Telemedicine Ltd. reported its financial results for the year ended December 31, 2024.
• The company appointed David Arnon as the new Chief Executive Officer in August 2024.
• The company is facing challenges, including a goodwill impairment in its German operations and a voluntary delisting from the Nasdaq.
• Revenue remained relatively stable at approximately $57 million in both 2024 and 2023.
• The company experienced a net loss of $27.75 million in 2024, compared to a net loss of $6.86 million in 2023.
• A significant factor contributing to the increased loss was an impairment loss of $13.5 million related to goodwill in the German operations.
• The company's cash and cash equivalents decreased from $26 million in 2023 to $18 million in 2024.
• The company is acquiring the remaining 30% stake in Mediton, but the transaction is currently disputed.
• The company voluntarily delisted from the Nasdaq Capital Market in April 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue is stable, the significant increase in net loss and the goodwill impairment in Germany are concerning. The voluntary delisting from the Nasdaq also raises questions about the company's future strategy. Overall, the sentiment is slightly negative.

Positives

• Revenue remained relatively stable year-over-year.
• The company is continuing to develop and market its SmartHeart platform in the U.S.
• The company is working to resolve the dispute over the Mediton acquisition.

Negatives

• The company experienced a significant increase in net loss from $6.86 million in 2023 to $27.75 million in 2024.
• A $13.5 million impairment loss was recognized related to goodwill in the German operations.
• Cash and cash equivalents decreased from $26 million in 2023 to $18 million in 2024.
• The company voluntarily delisted from the Nasdaq Capital Market in April 2025.
• The company is acquiring the remaining 30% stake in Mediton, but the transaction is currently disputed.

Risks

• The company faces risks related to its operations in Israel, including military instability and political conditions.
• The company is subject to evolving governmental regulations in the healthcare industry.
• The company faces intense competition in the telemedicine market.
• The company's proprietary rights may be challenged.
• The company may fail to retain key personnel and attract additional qualified healthcare and management personnel.
• The company may encounter data security and privacy risks.
• The company's financial results may be affected by fluctuations in exchange rates.
• The company may be affected by the failure of key suppliers and sub-contractors.
• The company must comply with tax laws in several jurisdictions.
• The market price for the company's ADSs and ordinary shares may be volatile.

Future Outlook

The company intends to continue to seek to enhance its growth by selectively acquiring cross-selling businesses that offer synergistic product lines and complementary technologies and services, such as the Mediton acquisition. We are continuously examining potential acquisition targets, including competitors, businesses with related technologies and certain operators of telemedicine centers.

Industry Context

The telemedicine market is rapidly evolving, with increasing competition and regulatory changes. SHL Telemedicine is positioning itself to meet the increasing demand for virtual healthcare, which is more efficient and less expensive than healthcare provided in traditional clinical environments.

Comparison to Industry Standards

• The document mentions competitors such as Natali, Philips Medical Systems, Teladoc, Otto Group Medgate, Vitaphone, Teleclinic, 4 sigma, and MD-Medicus.
• The document references clinical studies that indicate that SHL Telemedicine's 12 lead ECG product and cardiac telemedicine services offer a higher quality of care to cardiac patients as measured by post myocardial infraction hospitalization mortality and readmission rates.
• The document references the Imperial College London TELE-ACS clinical trial and the HELP-MI trial conducted by the Mayo Clinic, which focused on the application of SmartHearts 12-lead ECG technology for monitoring of post-MI (heart attack) patients at home.

Management Changes

Legal Proceedings

• The company is acquiring the remaining 30% stake in Mediton, but the transaction is currently disputed.
• A financial claim was filed with the Tel Aviv Regional Labor Court against Mediton, and Dr. Haim Perlock by the former CEO of Mediton.

Related Party Transactions

• The office space leased by our Mediton business in Israel is owned by an affiliate of a former shareholder in Mediton.
• In September 2024, our shareholders, following the approval of the Compensation Committee and the Board, approved Mr. David Arnons terms of office as Chief Executive Officer.

Stakeholder Impact

• Shareholders may be concerned about the company's increased net loss and the voluntary delisting from the Nasdaq.
• Employees may be affected by the restructuring and cost-cutting measures.
• Customers may be impacted by changes in the company's product and service offerings.

Next Steps

• The company will continue to focus its efforts on driving the growth of its operations in the German and Israeli markets.
• The company will continue to promote the SmartHeart platform technology in the U.S. and elsewhere.
• The company will continue to seek to enhance its growth by selectively acquiring cross-selling businesses that offer synergistic product lines and complementary technologies and services.
• The company will work to resolve the dispute over the Mediton acquisition.

Key Dates

Keywords

telemedicine, financial results, SHL Telemedicine, David Arnon, Mediton, goodwill impairment, Nasdaq delisting, SmartHeart, healthcare, Israel, Germany, USA